Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

In a historic first, a therapy developed by Summit Therapeutics beat Merck blockbuster Keytruda in late-stage lung cancer ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...

A bounding pulse is when your heart beats strongly. You may feel your pulse in your neck, wrist, or foot. Here’s why it ...

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment ...

Heart palpitations without other symptoms may be related to anxiety or too much caffeine. If you’re unsure, read on to learn ...

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

In a report released on September 11, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – ...

Hepatitis E virus (HEV) is a small RNA virus with a significant impact on global health, responsible for approximately 20 million infections annually, with 3.3 million symptomatic cases and around 44, ...